[Primary and secondary prevention in hypertensive patients. An assessment of current status].
The effect of a long-term treatment with beta-receptor-antagonists after an established myocardial infarction is generally accepted. Beta-receptor-antagonists without intrinsic sympathicomimetic activity should be used, cardioselectivity is of lesser importance, except in patients with special problems (i.e. increased bronchial resistance, decreased peripheral blood flow etc.). Hydrophilic or lipophilic properties do not play any role. For primary prophylaxis in older hypertensives diuretics are the drugs of first line, in patients with high risk for heart- and blood-vessel diseases however beta-receptor-antagonists--eventually in combination with low doses of diuretics-should be chosen.
Gesellschaft für klinische Pharmakologie, Wien.
G
G
Hitzenberger
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000188:drug therapy*
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents
Primär- und Sekundärprävention bei Hypertonikern. Eine Bestandsaufnahme.